Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents.

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Biotechnology

zPREDICTA

Mina Bissell

Robert Tressler

Amrita Krishnan

Karen Reckamp

Tom Kelly

The executive team at zPREDICTA has a history of experience in the predictive oncology industry and cancer research. The team is composed of individuals with a background in genetics and molecular and cell biology from prestigious universities. This experience and education gives the team the skills necessary to conduct cutting-edge research in predictive oncology and develop innovative products to help cancer patients.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at zPREDICTA

Leadership Team

Board of Directors